Salisbury R&D Tax Credit Overview for Businesses

R&D Tax Credits for Salisbury, Maryland Businesses

Salisbury, Maryland, thrives in industries such as healthcare, education, manufacturing, and retail. Top companies in the city include Peninsula Regional Medical Center, a major healthcare provider; Salisbury University, a key educational institution; Perdue Farms, a prominent manufacturing company; Walmart, a global retail giant; and Amazon, a global logistics and e-commerce company. The R&D Tax Credit can benefit these industries by reducing tax liabilities, fostering innovation, and improving business performance. By leveraging the R&D Tax Credit, companies can reinvest savings into advanced research boosting Salisbury’s economic growth.

find out more

Are you eligible?

Why choose us?

Pass an Audit?

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed’s office location at 145 West Ostend Street, Baltimore, Maryland is less than 115 miles away from Salisbury and provides R&D tax credit consulting and advisory services to Salisbury and the surrounding areas such as: Cambridge, Easton, Ocean Pines, Ocean City and Westminster.

If you have any questions or need further assistance, please call or email our local Maryland Partner on (443) 687-8701.
Feel free to book a quick teleconference with one of our Maryland R&D tax credit specialists at a time that is convenient for you. Click here for more information about R&D tax credit management and implementation.

Schedule a Teleconference

Salisbury, Maryland Patent of the Year – 2024/2025

Drug Delivery Co., LLC has been awarded the 2024/2025 Patent of the Year for its innovation in sustained-release drug delivery. Their invention, detailed in U.S. Patent No. 12083217, titled ‘Method of fabricating an extended release subcutaneous medicinal dosage implant system’, outlines a novel approach to creating biodegradable implants that release medication over extended periods.

The patented method involves combining a medicinal agent with specific polymers to form a homogeneous mixture. This mixture is then processed through a segmented screw extruder and formed into implants using a mini-jet system. The process ensures a smooth, defect-free implant surface, enhancing biocompatibility. Notably, the inclusion of polyethylene glycol reduces the risk of biofouling, improving the implant’s performance in the body.

This advancement holds promise for treating conditions requiring long-term medication administration, such as opioid use disorder. By providing a controlled release of drugs like naltrexone, the implants could improve patient adherence and outcomes. The technology represents a significant step forward in drug delivery systems, potentially transforming how chronic conditions are managed.